ContraVir Pharmaceuticals, Inc. (CTRV) Stock: Seeing Declines In Today’s Session


ContraVir Pharmaceuticals, Inc. (CTRV) is working its way for to the bottom in the market in today’s trading session. The stock, one that is focused in the biotech industry, is currently trading at $7.95 after heading down -16.32% so far today. As it relates to biotechnology companies, there are several aspects that have the potential to lead to price movement in the market. News is one of the most common reasons for movement. Here are the most recent headlines relating to CTRV:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-11-19 02:29PM Why Low-Float, Thinly Traded ContraVir Pharma’s Rally Is Continuing
08:30AM ContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis B
Jun-07-19 02:27PM Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today
Jun-06-19 11:44AM ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study
08:00AM ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis

However, any time investors are making an investing decision, prospective investors should look at much more than just news, especially in the generally speculative biotech sector. Here’s what’s happening in regard to ContraVir Pharmaceuticals, Inc..

Recent Movement From CTRV

Although a move down on a single session, like what we’re seeing from ContraVir Pharmaceuticals, Inc. may lead to fear in some investors, that by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It’s always important to look into trends just a single trading session. When it comes to CTRV, here are the returns on investment that investors have seen:

  • Past Seven Days – Over the past five trading sessions, CTRV has generated a change in value in the amount of 59.00%.
  • Monthly – The monthly performance from ContraVir Pharmaceuticals, Inc. works out to -11.27%.
  • Past 3 Months – Throughout the last quarter, the company has generated a return that comes to -57.94%
  • Bi-Annually – In the past 6 months, we have seen a performance that amounts to -74.77% from the company.
  • This Year So Far – Since the open of this year CTRV has generated a return on investment of -59.73%.
  • Full Year – Finally, in the last year, investors have seen a change in the amount of -92.35% out of CTRV. Throughout this period of time, the stock has sold at a high of -93.44% and a low price of 65.62%.

Important Ratios

Digging into various ratios having to do with a company generally gives investors a view of how dangerous and/or potentially profitable a pick might be. Here are some of the important ratios to look at when looking at CTRV.

Short Ratio – The short ratio is a measure of short interest. As the ratio heads up, it means that more investors believe that the value of the stock is headed for declines. Across the sector, biotech stocks tend to come with a higher short ratio. However, we also tend to see a lot of short squeezes in the industry. Nonetheless, when it comes to ContraVir Pharmaceuticals, Inc., the stock’s short ratio comes to 0.00.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Essentially, they measure whether or not a company can pay its debts as they mature using quick assets or current assets. In the biotech space, several companies are reliant on the continuation of investor support, the current and quick ratios can look upsetting. Nonetheless, quite a few better companies in the biotech sector come with strong current and quick ratios. In terms of CTRV, the quick and current ratios come to 0.60 and 0.60 respectively.  

Book To Share Value – The book to share value compares the the share price to the book value of assets that are owned by the company. In the case of ContraVir Pharmaceuticals, Inc., that ratio equates to -4.47.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Several early stage biotechnology companies struggle to keep cash on hand. So, if you’re interested in a stock in the biotech sector, this is an important ratio to consider. In this case, the cash to share value ratio comes to 3.21.

What Analysts Think About ContraVir Pharmaceuticals, Inc.

Although it’s rarely a good idea to blindly follow the opinions of analysts, it is a smart idea to use their thoughts when validating your own due diligence when it comes to making an investment decision in the biotech space. Here are the most recent moves that we’ve seen from analysts when it comes to CTRV.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-10-18 Upgrade Maxim Group Hold → Buy $3
Feb-13-18 Downgrade Maxim Group Buy → Hold
May-06-16 Initiated Maxim Group Buy $4

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CTRV, here’s what we’re seeing:

Institutions own 1.10% of the company. Institutional interest has moved by -46.17% over the past three months. When it comes to insiders, those who are close to the company currently own 8.00% percent of CTRV shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

Float Information

Investors and traders tend to like to know the counts of shares both outstanding and available. In terms of ContraVir Pharmaceuticals, Inc., currently there are 0.53M and there is a float of 0.48M. These data mean that of the total of 0.53M shares of CTRV currently in existence today, 0.48M are able to be traded in the public realm.

I also find it important to take a look at the short percent. After all, when a large percentage of the float is shorted, the overall feeling among traders is that the stock is going to take a dive. As far as CTRV, the percentage of the float that is sold short comes to a total of 0.31%. Most traders believe that a concerning short percent of the float is considered to be anything over 40%. Nonetheless, I’ve seen that a short ratio over 26% is usually a a play that could prove to be very risky.

Financial Results And Expectations

What have ween seen from CTRV in terms of financial results?Here’s what you need to know:

  • Analyst Expectations – Currently, analysts have expectations that CTRV will report earnings per diluted share that comes to -0.47, with 0 to be reported in the earnings announcement for the current quarter. Although this information is not earnings driven, because we are chatting about analysts, ContraVir Pharmaceuticals, Inc. is currently graded as a 3.00 considering a scale that ranges from 1 to 5 on which 1 is the poorest Wall Street analyst grade and 5 is the best possible rating.
  • 5-Year Sales – In the past 5 years, ContraVir Pharmaceuticals, Inc. has created a change in sales that works out to 0. Earnings per diluted share over the past half decade have seen a change of 16.30%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings performance, or Q/Q data as it is often referred to as in today’s society, the company has seen a change in earnings that comes to a total of 56.80%. CTRV has also experienced movement in terms of sales that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. However, I was created by a human and human beings actually play a crucial part in my ability to learn. Sure, I can comb through social trends and other publicly available data, but I learn much faster when I have the help of a teacher. If you’d like to help me learn something, I would love to learn! Is there other data that captures your interest? Am I saying something wrong? Is there another way to look at data? If so, leave a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here